multiple-sclerosis-research.org /1 month ago

Entering the CNS for fenebrutonib

As Brutons tyrosine kinase is supposed to target B cells and macrophages and macrophages in the brain may be important for progression, it is important to show that there is brain...

Read source
multiplesclerosisnewstoday.com /4 weeks ago

Experimental therapy may curb chronic brain inflammation in MS

Genentech’s experimental oral therapy fenebrutinib may help control the chronic inflammation in the brain associated with disability progression in both relapsing forms of multiple...

Read source
multiplesclerosisnewstoday.com /1 month ago

FDA grants priority review to ‘high-efficacy’ drug for 2 types of MS

The U.S. Food and Drug Administration (FDA) has agreed to review an application from Roche seeking approval of its BTK inhibitor fenebrutinib as a treatment for relapsing forms of...

Read source
biopharmadive.com /1 month ago

FDA starts review of Roche’s multiple sclerosis pill

The FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety questions still hang over Roche’s program.

Read source
multiple-sclerosis-research.org /4 weeks ago

Remibrutinib LATE BREAKING ABSTRACT becomes an Instant Paper

Weindl et al. Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials Lancet Online firstOctober 23, 2026Open ac...

Read source
qchron.com /1 month ago

Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication f...

INDIANAPOLIS, Oct. 2, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication...

Read source
multiplesclerosisnewstoday.com /2 weeks ago

Experimental MS therapy outperforms approved treatment in two trials

The experimental oral therapy remibrutinib significantly reduced relapse rates and brain lesion activity more than the approved therapy Aubagio (teriflunomide) in two Phase 3 clini...

Read source
healio.com /1 month ago

FDA approves Atebrioz for fibrodysplasia ossificans progressiva

Editor’s note: This is a developing story. Please check back soon for updates.The FDA approved zilurgisertib tablets for the reduction of heterotopic ossification among patients ag...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.